Search the Newsreel

Chemours Jumps 5.4% After JP Morgan Maintains Neutral

The Chemours Company (NYSE:CC) saw its shares jump 5.4% despite three major Wall Street firms cutting their price targets. JP Morgan, BMO Capital, and UBS all revised their outlooks, with JP Morgan maintaining a Neutral rating and lowering its target to $15. The market …

Chemours Expands Low-GWP Refrigerant Portfolio for Data Centers

The Chemours Company CC has launched Opteon ZE (R-1234ze(E)) and Opteon 515B (R-515B) for stationary chiller applications, targeting the growing cooling requirements of AI-driven data center infrastructure. The new products expand Chemours' portfolio of low-global-warming-potential (GWP) refrigerants and strengthen its positioning in cooling markets. …

Analysts Offer Insights on Materials Companies: Chemours Company (CC), Pan American Silver (PAAS) and West Fraser Timber Co (WFG)

BMO Capital analysts have provided ratings for three materials companies: Chemours Company (CC), Pan American Silver (PAAS), and West Fraser Timber Co (WFG). John McNulty maintained a Buy rating on Chemours with an $18 price target, while Matt Murphy set a Hold rating on …

Chemours president Gerardo Familiar buys $30,050 in stock

Gerardo Familiar Calderon, President of Advanced Performance Materials at The Chemours Company, recently purchased 1,935 shares of the company's common stock for $30,050. This acquisition follows a nearly 25% drop in the stock price over the past six months and occurs amid mixed Q2 …

Chemours Co (NYSE: CC) CAO has 2,426 shares withheld to cover tax on RSU vesting

Chemours Co's Chief Accounting Officer, David Will, reported a Form 4 transaction where 2,426 shares of common stock were withheld to cover tax obligations arising from the vesting of restricted stock units and dividend equivalent units. This transaction, valued at $15.24 per share, was …

California alleges DuPont used spin-off companies to avoid PFAS liability

California's attorney general, Rob Bonta, has updated a 2022 lawsuit against DuPont and its spin-off companies, alleging fraudulent corporate restructuring to avoid PFAS liabilities. The state claims DuPont shifted liabilities to Chemours, a company with fewer assets, through two memoranda of understanding in 2021 …

Chemours (CC) Stock Stays Cheap On A 48% Three Year Slump

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Chemours stock has delivered a steep 48.2% decline over the past three years, yet its current valuation checks lean cheap. This sets up …

Chemomab Therapeutics (CMMB) gains 5.2% stake holder in Touchstone Global

Touchstone Global Investments Pty Ltd has reported a 5.2% passive stake in Chemomab Therapeutics Ltd. (CMMB), holding 377,814 American Depositary Shares (ADSs). This disclosure, filed on a Schedule 13G, indicates that Touchstone Global has sole voting and dispositive power over these shares, with each …

Chemours (NYSE:CC) Cut to "Strong Sell" at Zacks Research

Zacks Research has downgraded Chemours (NYSE:CC) from a "strong-buy" to a "strong sell" rating. This downgrade follows Chemours' recent quarterly earnings report where the company missed analyst estimates for both EPS and revenue. Despite the downgrade, other analysts maintain a "Hold" rating with a …

Reliance Chemotex Q1 Results: Net Profit Rises 36% YoY to ₹1.37 crore

Gov. Stein, AG Jackson oppose Chemours, EPA 'deal'

North Carolina Governor Josh Stein, Attorney General Jeff Jackson, and DEQ Secretary Reid Wilson have voiced strong opposition to a proposed settlement between the EPA and Chemours regarding PFAS contamination. They argue the deal was brokered without consulting North Carolina, offers minimal benefits to …

Chemours Co (CC) director Cranston purchases 6,000 shares in open-market trade

Chemours Co director Mary B. Cranston purchased 6,000 shares of common stock at $15.825 per share on August 7, 2026, in an open-market transaction. Following this purchase, her beneficial ownership of Chemours common stock increased to 113,140.9469 shares, which includes directly owned shares, restricted …

Chemours launches two refrigerants for data center chillers

Chemours has introduced two new low-GWP refrigerants, Opteon ZE and Opteon 515B, designed for data center chillers and other large-scale cooling applications. These products aim to provide environmentally friendly alternatives for companies transitioning from higher global warming potential refrigerants. The company emphasizes the importance …

Chemours Stock Moves as Narrow Q2 Net Loss Offsets Missed Earnings Estimates

Chemours (CC) stock saw movement after reporting a narrower net loss of $274 million in Q2, an improvement from the previous year, despite missing adjusted earnings and revenue estimates. The company's segment results were mixed, with growth in Titanium Technologies and Performance Solutions (driven …

Chemours' Q2 Earnings & Revenues Lag Estimates on Lower Volumes

The Chemours Company CC reported a net loss of $274 million or a loss of $1.81 per share for the second quarter of 2026. This compares favorably with the year-ago quarter's net loss of $380 million or a loss of $2.53 per share. Barring …

Reliance Chemotex Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Reliance Chemotex re-appoints Sanjiv Shroff as MD for 3 years

Hemogenyx Pharmaceuticals (HEMO) Finalizes CAR-T Collaboration with Cellin Technologies for HG-CT-1 Therapy in Estonia

Chemours Co (CC) CFO Shane Hostetter Buys 3,350 Shares

Chemours Co's CFO, Shane Hostetter, recently purchased 3,350 shares of the company stock, signaling strong insider confidence. This transaction, executed at $14.94 per share, increases his direct ownership to over 102,000 shares. The stock is currently deemed "Modestly Undervalued" by GuruFocus's GF Value model, …

Chemours Co (NYSE: CC) CFO purchases 3,350 shares in open-market trade

Chemours Co's Chief Financial Officer, Shane Hostetter, purchased 3,350 shares of common stock on August 6, 2026, at a price of $14.94 per share. This transaction increased his total beneficial ownership to 102,697.7058 shares, including restricted stock units and dividend equivalent units. The purchase …

Chemours Co (CC) CFO withholds 3,087 shares to satisfy tax obligations

Chemours' Medium-Term Growth Less Certain as Refrigerant Business Sees Larger Destocking, UBS Says

Chemours' (CC) recent financial results have cast less certainty on its medium-term growth, with its refrigerant business seeing larger destocking in the quarter, UBS said in a note emailed Monday.The company's refrigerant business gained temporary market share with an oversell Silver Upgrade to read …

The Chemours Company Launches Opteon Ze and Opteon 515B Refrigerants for Chiller Applications

The Chemours Company has introduced two new low-global warming potential (GWP) refrigerants, Opteon ZE and Opteon 515B, for stationary chiller applications. These products are designed to meet the increasing cooling demands of large-scale infrastructure, including data centers, driven by the growth of AI and …

Chemomab Therapeutics (CMMB) holder Erik Otto reports 1.2% ADS ownership

Erik Otto, an investor in Chemomab Therapeutics Ltd. (CMMB), has filed an amended Schedule 13G, disclosing beneficial ownership of 90,000 American Depository Shares (ADSs), which represents 1.2% of the company's outstanding ADSs. Each ADS represents twenty ordinary shares. Otto holds sole voting and dispositive …

Chemours downgraded at UBS as refrigerants reset clouds outlook

[Petrochemical Plant Illuminated at Dusk] Bim/E+ via Getty Images UBS downgraded Chemours (CC [https://seekingalpha.com/symbol/CC]) to Neutral from Buy and slashed its price target, saying a sharper-than-expected reset in the chemical maker’s refrigerants business has reduced confidence in its medium-term growth outlook. Shares of Chemours …

Chemours Launches Opteon™ ZE and Opteon™ 515B Refrigerants for Chiller Applications Powering Data Centers, Commercial Buildings, and Other Mission Critical Environments

New additions to the Opteon™ portfolio support high-performance, sustainable cooling solutions in stationary chillers for AI-driven data centers, and commercial HVAC applications WILMINGTON, Del., Aug. 10, 2026 /PRNewswire/ -- The Chemours Company (Chemours) (NYSE: CC), a global chemistry company, today announced the launch of …

Don't Buy The Chemours Company (NYSE:CC) For Its Next Dividend Without Doing These Checks

The Chemours Company (NYSE:CC) is set to trade ex-dividend soon, with a payment of US$0.0875 per share, resulting in a 2.2% trailing yield. While the dividend is well-covered by free cash flow (25% payout), the company reported a loss last year and has shown …

ChemoMetec enters collaboration agreement with Roche Diagnostics

Chemometec A/S ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today …

Chemours Company (The) Stock 12‑Month Price Target Cut to $22.5, Implies 43% Upside

The average 12-month price target for Chemours Company (The) stock has been revised down to $22.5 from $22.8, based on estimates from 10 analysts. This updated target suggests a potential upside of approximately 43% from the August 7 closing price. Despite the target cut, …

Chemours Co (CC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Chemours’ (CC) Dividend Amid Forecast Net Losses: Sensible Capital Return Or Mixed Signal?

Chemomab Therapeutics Ltd (CMMB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Chemomab Therapeutics Ltd (CMMB) has a "Strong Buy" rating based on 2 analysts, with a target price of USD 26.50, representing a potential upside of 733.33%. The company's previous quarter's EPS was USD -0.24, slightly below the market expectation of USD -0.22, with the …

The Chemours Company

A federal judge has approved over $2.5 billion in settlements between New Jersey and several companies, including DuPont, Chemours, Corteva, and 3M. These settlements aim to resolve claims related to pollution caused by PFAS, commonly known as "forever chemicals." The Chemours Company was specifically …